Lineage Cell Therapeutics (NYSEAMERICAN:LCTX) Earns Buy Rating from D. Boral Capital

Lineage Cell Therapeutics (NYSEAMERICAN:LCTX)‘s stock had its “buy” rating reissued by D. Boral Capital in a research report issued on Monday,Benzinga reports. They presently have a $2.00 price objective on the stock. D. Boral Capital’s price objective would indicate a potential upside of 17.65% from the company’s previous close.

Separately, HC Wainwright reiterated a “buy” rating and issued a $9.00 price target on shares of Lineage Cell Therapeutics in a research note on Monday, November 24th. Three analysts have rated the stock with a Buy rating, Based on data from MarketBeat.com, Lineage Cell Therapeutics has an average rating of “Buy” and a consensus target price of $4.67.

Lineage Cell Therapeutics Stock Performance

NYSEAMERICAN LCTX opened at $1.70 on Monday. Lineage Cell Therapeutics has a 52 week low of $0.37 and a 52 week high of $2.09. The stock’s 50 day moving average price is $1.68 and its two-hundred day moving average price is $1.55. The stock has a market capitalization of $391.56 million, a price-to-earnings ratio of -5.86 and a beta of 1.80.

Lineage Cell Therapeutics (NYSEAMERICAN:LCTX) last posted its quarterly earnings data on Thursday, November 6th. The company reported ($0.13) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.02) by ($0.11). The business had revenue of $3.68 million during the quarter, compared to analyst estimates of $2.30 million. Lineage Cell Therapeutics had a negative net margin of 625.53% and a negative return on equity of 72.02%. On average, equities research analysts forecast that Lineage Cell Therapeutics will post -0.12 EPS for the current year.

Hedge Funds Weigh In On Lineage Cell Therapeutics

A number of hedge funds and other institutional investors have recently bought and sold shares of the business. SG Americas Securities LLC acquired a new stake in Lineage Cell Therapeutics during the 4th quarter worth approximately $25,000. Citizens Financial Group Inc. RI acquired a new stake in shares of Lineage Cell Therapeutics during the third quarter worth $25,000. Jump Financial LLC bought a new stake in shares of Lineage Cell Therapeutics in the second quarter valued at about $28,000. Cannon Global Investment Management LLC bought a new stake in shares of Lineage Cell Therapeutics in the second quarter valued at about $30,000. Finally, Integrity Alliance LLC. grew its stake in shares of Lineage Cell Therapeutics by 75.0% in the second quarter. Integrity Alliance LLC. now owns 35,000 shares of the company’s stock valued at $32,000 after acquiring an additional 15,000 shares in the last quarter. Institutional investors own 62.47% of the company’s stock.

Lineage Cell Therapeutics Company Profile

Lineage Cell Therapeutics is a clinical-stage biotechnology company developing novel, allogeneic cell therapies built on pluripotent stem cell platforms. The company focuses on three primary therapeutic areas—retinal disease, neural repair and immune-effector cell oncology—leveraging its proprietary manufacturing processes to create off-the-shelf cell therapy candidates designed for broad patient populations.

Its lead candidate, OpRegen, comprises retinal pigment epithelium cells intended to slow or reverse vision loss in patients with geographic atrophy secondary to age-related macular degeneration.